New drug combo targets rare liver cancer in teens and adults
NCT ID NCT06027086
Summary
This study is testing whether combining two drugs—DRP-104 and durvalumab—is safe and can shrink tumors in people with advanced fibrolamellar hepatocellular carcinoma (FLC), a rare liver cancer. It will enroll about 27 patients aged 12 and older whose cancer has progressed despite prior immunotherapy. Researchers will measure how many patients see their tumors shrink and monitor side effects and survival.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for FIBROLAMELLAR HEPATOCELLULAR CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Johns Hopkins SKCCC
RECRUITINGBaltimore, Maryland, 21231, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.